Posts Tagged ‘subsidy and delisting protection’

NZ DOCTOR:  Restrictions on access to intravenous prostate cancer treatment drug Zoladex (goserelin) will be lifted tomorrow in an agreement that sees Pharmac continuing to fully subsidise the drug. As part of the same agreement with manufacturer AstraZeneca, a special authority will no longer be required for  the drug, which will have subsidy and delisting protection until June 30, 2013. READ MORE>

Read Full Post »